Combined effects of different interleukin‐28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection
Janett Fischer, Stephan Böhm, Markus Scholz, Tobias Müller, Heiko Witt, Jacob George, Christoph Sarrazin, Simone Susser, Eckart Schott, Vijayaprakash Suppiah, David R. Booth, Graeme J. Stewart, Florian van Bömmel, Annika Brodzinski, Balazs Fülöp, Pascal Migaud, Thomas Berg – 11 January 2012 – In patients with chronic hepatitis C virus (HCV) infection, several variants of the interleukin‐28B (IL28B) gene have been shown to correlate significantly with a sustained virologic response (SVR).